GYRE: Gyre Therapeutics, Inc. Stock

by  •  • Comments Off on GYRE: Gyre Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 743.28
Enterprise Value ($M) 766.55
Book Value ($M) 98.40
Book Value / Share 1.05
Price / Book 7.55
NCAV ($M) 37.78
NCAV / Share 0.40
Price / NCAV 19.67

Profitability (mra)
Return on Invested Capital (ROIC) 0.12
Return on Assets (ROA) 0.10
Return on Equity (ROE) 0.14

Liquidity (mrq)
Quick Ratio 2.99
Current Ratio 3.32

Balance Sheet (mrq) ($M)
Current Assets 64.79
Assets 125.41
Liabilities 27.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 105.76
Operating Income 16.23
Net Income 12.09
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -3.64
Cash from Investing -19.88
Cash from Financing 2.10

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
09-06 13D Ma Songjiang 7.62
09-06 13D Luo Ying 8.54

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 24,089 96,861 24.87
2025-04-16 28,076 70,065 40.07
2025-04-15 30,092 86,570 34.76

(click for more detail)

Similar Companies
GOVX – GeoVax Labs, Inc. GRCE – Grace Therapeutics, Inc.
GTBP – GT Biopharma, Inc. HCWB – HCW Biologics Inc.
HEPA – Hepion Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io